Ivermectin
Last Updated: 12/15/24
Last Updated: 12/6/24
Status: Solid Tumor and NF2 Clinical Trial
Administered By:
Pill - Oral (morning)
Tumor Target:
Solid Tumors; Worms Larva
Inhibits:
anaplastic lymphoma kinase (ALK) and
epidermal growth factor receptor (EGFR) inhibitor
Introduction
Ivermectin is a treatment for "Strongyloidiasis is an underdiagnosed and preventable life-threatening disease caused by infection with the helminth Strongyloides
stercoralis. Chronic asymptomatic infection can be sustained for decades, and immunosuppression can lead to disseminated infection, with a mortality rate of 70% - 100%.
In the neurosurgical population, corticosteroids are the most consistent cause of hyperinfection."[1]
"What is strongyloidiasis?
"Strongyloidiasis is an infection with Strongyloides, a parasitic worm. It's sometimes called Strongy. The worm gets into your body through your skin and makes its way
to your lungs and intestines, where it matures and reproduces.
Some infections can last for years. It can cause skin or digestive symptoms that come and go (intermittent) or no symptoms at all. If you have a weakened immune system,
strongyloidiasis can be life-threatening."[2]
Lawsuit
https://evaluation.forthepeople.com/depo_provera/getstarted/quiz?utm_source
https://www.facebook.com/MMForthePeople
Sources
-
FDA."Ivermectin and COVID-19"
https://www.fda.gov/consumers/consumer-updates/ivermectin-and-covid-19
-
Dominguez, Victor Rodriguez, et al. "Strongyloides hyperinfection syndrome due to corticosteroid therapy after resection of meningioma: illustrative
case." Journal of Neurosurgery: Case Lessons 4.2 (2022).
https://thejns.org/caselessons/view/journals/j-neurosurg-case-lessons/4/2/article-CASE21667.xml
-
Cleveland Clinic. "What is strongyloidiasis?" (Last Seen: 12/02/24)
https://my.clevelandclinic.org/.../14074-strongyloidiasis
-
Seegerweiss. "Depo-Provera Brain Tumor Lawsuit" https://www.seegerweiss.com/.../depo-provera-brain...
/...
-
Khan, Md Saiful Islam, et al. "Ivermectin treatment may improve the prognosis of patients with COVID-19." Archivos de bronconeumologia 56.12
(2020): 828. https://pmc.ncbi.nlm.nih.gov/articles/PMC7837160/